VCM
TVTX icon

Voleon Capital Management’s Travere Therapeutics TVTX Stock Holding History

Voleon Capital Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.27M Buy
145,655
+102,300
+236% +$4.54M 0.15% 141
2026
Q1 		$1.29M Sell
43,355
-59,198
-58% -$1.77M 0.03% 400
2025
Q4 		$3.92M Buy
+102,553
New +$3.33M 0.08% 230

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Voleon Capital Management's TVTX Position: Q2 2026 in Review

Voleon Capital Management increased its Travere Therapeutics (TVTX) stake by 236% in Q2 2026, buying an estimated $4.54M and bringing the position to 145,655 shares worth $8.27M. The position accounts for 0.15% of the portfolio, ranked #141.

Voleon Capital Management first reported a position in TVTX in Q4 2025 and has held it in 3 quarters since. 320 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Voleon Capital Management held 145,655 shares of Travere Therapeutics worth $8.27M as of Q2 2026.
  • Voleon Capital Management bought 102,300 Travere Therapeutics shares in Q2 2026, an estimated $4.54M.
  • Travere Therapeutics made up 0.15% of Voleon Capital Management's portfolio in Q2 2026, its #141 holding.
  • Voleon Capital Management first reported a position in Travere Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 320 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Voleon Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.